Key facts
- Orca Bio’s last known valuation is $1.2B (Jun 2020).
- It has raised $625.0M; the latest was Later Stage VC ($250.0M) in Jan 2026.
- Notable investors include Lightspeed Venture Partners, 8VC, StartX (US), Felicis, DCVC — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Orca Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Orca Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Orca Bio
Developer of cell therapy products designed to replace patients' diseased blood and immune systems with healthy ones. The company specializes in the research and development of novel cell therapies that help to transform all aspects of bone marrow transplant and create a life-saving platform for many diseases, enabling healthcare professionals to efficiently treat their patients.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2015
- Employees
- 297
- Website
- orcabio.com/
- Ownership
- Privately Held (backing)
Orca Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Orca Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Orca Bio in its N-PORT filings yet. We sweep new filings monthly.